

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: William C. Olson and Paul J. Maddon

Serial No.: 09/828,615 Examiner: Jeffrey Stucker

Filed: April 6, 2001 Group Art Unit: 1648

For: METHODS FOR INHIBITING HIV-1 INFECTION

1185 Avenue of the Americas New York, New York 10036

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Progenics Pharmaceuticals, Inc. ("Progenics"), 777 Old Saw Mill River Road, Tarrytown, New York 10591, is the assignee of record of the entire right, title and interest in the above-identified application by virtue of an assignment from William C. Olson and Paul J. Maddon, which assignment was recorded in the U.S. Patent and Trademark Office on July 27, 2001 at Reel No. 012029, Frame 0257, and a copy of which is attached hereto as **Exhibit A**.

Progenics hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the subject application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173 of any patent granted on U.S. Serial No. 10/116,797, filed April 5, 2002, and hereby agrees that any patent issued from the subject application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to any patent granted on U.S. Serial No. 10/116,797, this agreement to run with any patent granted on the subject application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, Progenics does not disclaim the

Applicants: William C. Olson and Paul J. Maddon

Serial No.: 09/825,615 Filed: April 6, 2001

Page 2

terminal part of any patent granted on the subject application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of any patent granted on U.S. Serial No. 10/116,797, in the event that any patent granted on U.S. Serial No. 10/116,797 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term.

I have reviewed the assignment attached hereto and certify that to the best of my knowledge and belief, Progenics has the entire right, title and interest in the subject application. I further certify that I am authorized to sign this Terminal Disclaimer on behalf of Progenics Pharmaceuticals, Inc.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: (JOJ

Progenics Pharmaceuticals, Inc.

By:

Paul J. Maddon, M.D., Ph.D. Chief Executive Officer

Progenics Pharmaceuticals, Inc.



OCTOBER 04, 2001

COOPER & DUNHAM LLP JOHN P. WHITE 1185 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036



UNITED STAYES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS



Washington, D.C. 20231

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

DOCKET CLERK

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 07/27/2001

REEL/FRAME: 012029/0257

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

OLSON, WILLIAM C.

DOC DATE: 04/24/2001

ASSIGNOR:

MADDON, PAUL J.

DOC DATE: 04/24/2001

ASSIGNEE:

PROGENICS PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NEW YORK 10591

SERIAL NUMBER: 09828615

PATENT NUMBER:

FILING DATE: 04/06/2001

ISSUE DATE:

STEVEN POST, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

SEP 3 0 2005 WOS - O	6-2001	y
FORM PTO-1595 (Substitute)	TIN BONG 88119 NON 61900 NON 1901	U.S. DEPARTMENT OF COMMERCE
(Rev. 8-96)		Patent and Trademark Office
To the Honorable Commissioner of Management of the Honorable Commissioner of the Honorable Commi		inal documents or copy thereof.
	300241	/ receiving party(ies):
William C. Olson	Sec. 1	
Paul J. Maddon	Name: Progenics	Pharmaceuticals, Inc.
	Internal Address:	
Additional name(s) of conveying partyles) adapted 3-9-2001	777	Old Saw Mill River Road
☐ Yes No	Street Address	Old Daw Mill River Road
		in Sec.
3. Nature of Conveyance:		5/3/3/3/3/3/
Assignment Merger	City/State/Zip. Tar	rytown. New York 10591
Security Agreement		·/// 2.7 max // //
Other	→ M 間間	JUL 2 7 2001 //
4/24/01; 4/24/01	Additional parma(s) & 20	dress(es) attached?
Execution Date(s):	Additional flame(s) a se	Arcas(as) saladay
4. Application number(s) or patent number(s): If this document is	being filed together with a	new application, the execution date(s) of the
application is(are):	<u> </u>	The state of the s
		The second section of the sect
A Patent Application No.(s) 09/828,615	B. Patent No.(s)	
filed April 6, 2001		
		,
		•
Additional numbers atta	sched? Yes 🗵	No
Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of appl	lications and patents involved:
Name:	2 7-10 4-0 /27 CED 53	.41):
Internal Address: Cooper & Dunham LLP	7. 10031 fee (37 CFR 93	40.00
1195 Avenue of the Americas	☐ Enclosed	•
Street Address: 1185 Avenue of the Americas		
	Authorized (to be charged to deposit account
City/State/Zip: New York New York 10036		
	8. Deposit account nun	iber.
	03-3125	<u> </u>
	SE THIS SPACE	
9. Statement and signature.	7	
To the best of my knowledge and belief, the foregoing info	mation is true and correct	and any attached copy is a true copy of the
original document.		
John P. White Reg. No. 28,678 Spencer Schneider Reg. No. 45,923		July 24, 2001
	iture	Date
Name of Person Signing Sign	V	
	Total Number of pages i	ncluding cover sheet, attachments and
I hereby certify that this correspondence is being deposited	document:3_	<u> </u>
this date with the U.S. Postal Service with sufficient postage		
as first class mail in an envelope addressed to:		
Commissioner of Patents and Trademarks, Washington,		
0C. 20231:		
AB 12-24-01		
John P. White Reg. No. 28,678 Date		
Speacer Schneider Reg. No. 45,923		•
OMB No. 0651-0011 (exp. 4/94)		
Mail documents to be recorded wi	th required cover sheet in	formation to:
	atents and Trademarks	

16/2001 ANNED1 00000035 033125 09828615

Box Assignments Washington, D.C. 20231

Assignment

In consideration of One Dollar (\$1.00), and other good and valuable considerations, the receipt of which is hereby acknowledged, we, the undersigned, William C. Olson residing at 21 Fawn Court, Ossining, New York 10562 and Paul J. Maddon residing at 191 Fox Meadow Road, Scarsdale, New York 10583

Hereby sell, assign and transfer to Progenics Pharmaceuticals, Inc.

a corporation of the State of

Delaware having a place of business at 777 01d Saw Mill River Road

Tarrytown in the County of Westchester and State of New York 10591, U.S.A.

its successors, assigns and legal representatives, the entire right, title and interest
for all countries, in and to any and all inventions which are disclosed and claimed,
and any and all inventions which are disclosed but not claimed, in the application for

United States Patent, which has been executed by the undersigned on April 24, 2001;
and is entitled

METHODS FOR INHIBITING HIV-1 INFECTION (U.S. Serial No. 09/828,615 , filed April 6, 2001)

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other applications for U.S. Letters Patent or other related property rights in any and all foreign countries which have been or shall be filed on any of said inventions disclosed in said application; and in and to all original and reissued patents or related foreign documents which have been or shall be issued on said inventions;

Authorize and request the Commissioner of Patents of the United States to issue to said Assignee, the corporation above named, its successors, assigns and legal representatives, in accordance with this assignment, any and all United States Letters Patent on said inventions or any of them disclosed in said application;

Agree that said Assignee may apply for and receive foreign Letters Patent or rights of any other kind for said inventions, or any of them; and may claim, in applications for said foreign Letters Patent or other rights, the priority of the aboresaid United States patent application under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention or under any other available international agreement; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned or the undersigned's executors or administrators will, for the United States and all foreign countries, execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications or other documents on any and all said inventions; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and representatives, all facts known and documents available to the undersigned relating to said inventions and the history thereof; testify in all legal proceedings; and generally do everything possible which said Assignee, ils successors, assigns or representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

	(Alle Lie	[L.S.]
24 (124)	200)	William C. Olson	
Date: april 24	•		
witness: Di Canio			
Jessica Dicanio			
44 cottag Drive			
Jarrytown NY 10591		Doub Maddon	[L.S.]
Dale: ARILDY	_200/	Paul J. Naddon	
Witness: BETM MANOCCHi		:	
50 BELLEVIEW AVE			
OSSININS, NY 105	62		
	•		

ASSIGNMENT

WILLIAM C. OLSON PAUL J. MADDON

2

PROGENICS PHARMACEUTICALS, INC.

Application for Letters Patent of the United States for:

METHODS FOR INHIBITING HIV-1 INFECTION

Attorney for John P. White

Cooper & Dunham LLP 1185 Avenue of the Americas New York, N.Y. 10036

212-278-0400